Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis

Journal of Drug Targeting

Volumn 19, Issue 3, 2011, Pages 219-227

  Saraogi, Gaurav Kant ^a   Sharma, Bhavna ^b   Joshi, Beenu ^b   Gupta, Pushpa ^b   Gupta, Umesh Dutta ^b   Jain, Narendra Kumar ^a   Agrawal, Govind Prasad ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

Author keywords

alveolar macrophages; isoniazid; mannose; targeting; Tuberculosis

Indexed keywords

DRUG CARRIER; ISONIAZID; MANNOSE; MANNOSYLATED GELATIN NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTITUBERCULAR ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG; LUNG ALVEOLUS MACROPHAGE; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SPLEEN; TUBERCULOSIS; ZETA POTENTIAL;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; FEMALE; GELATIN; ISONIAZID; MANNOSE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM INFECTIONS; NANOPARTICLES; PARTICLE SIZE; SURFACE PROPERTIES; TUBERCULOSIS;

EID: 79952674674     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.492522     Document Type: Article

References (25)

1. Agashe HB, Dutta T, Garg M, Jain NK. (2006). Investigations on the toxicological profle of functionalized ffth-generation poly (propylene imine) dendrimer. J Pharm Pharmacol, 58, 1491-1498. (Pubitemid 44785538)
2. Ahmad Z, Pandey R, Sharma S, Khuller GK. (2008). Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole-and moxifoxacin-loaded PLG nanoparticles. Int J Antimicrob Agents, 31, 142-146.
3. Coester CJ, Langer K, Van-Briesen H, Kreuter J. (2000). Gelatin nanoparticles by two-step desolvation\a new preparation method, surface modifcations and cell uptake. J Microencap, 17, 187-193. (Pubitemid 30135796)
4. Couvreur P, Fattal E, Andremont A. (1991). Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res, 8, 1079-1086.
5. Davis BG, Robinson MA. (2002). Drug delivery systems based on sugar macromolecule conjugates. Curr Opin Drug Discov Dev, 5, 279-288. (Pubitemid 35012714)
6. Deol P, Khuller GK. (1997). Lung specifc stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta, 1334, 161-172. (Pubitemid 27117518)
7. Desiderio JV, Campbell SG. (1983). Liposome-encapsulated cephalothin in the treatment of experimental murine salmonellosis. J Reticuloendothel Soc, 34, 279-287. (Pubitemid 14249466)
8. Gaspar MM, Cruz A, Penha AF, Reymão J, Sousa AC, Eleutério CV, Domingues SA, Fraga AG, Filho AL, Cruz ME, Pedrosa J. (2008). Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents, 31, 37-45. (Pubitemid 350245738)
9. Gelperina S, Kisich K, Iseman MD, Heifets L. (2005). Te potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med, 172, 1487-1490. (Pubitemid 43076534)
10. Guillaumont M, Leclercq M, Frobert Y, Guise B, Harf R. (1982). Determination of rifampicin, desacetylrifampicin, isoniazid and acetylisoniazid by high-performance liquid chromatography: application to human serum extracts, polymorphonucleocytes and alveolar macrophages. J Chromatogr, 232, 369-376. (Pubitemid 13190686)
11. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. (2008). Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specifc delivery. Nanomedicine, 4, 41-48. (Pubitemid 351324205)
12. Kaur A, Jain S, Tiwary AK. (2008). Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm, 58, 61-74. (Pubitemid 351419158)
13. Kumar PV, Asthana A, Dutta T Jain NK. (2006). Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target, 14, 546-556. (Pubitemid 44592888)
14. Nahar M, Mishra D, Dubey V, Jain NK. (2008). Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomed Nanotech Biology Med, 4, 252-261.
15. Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP. (2009). Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target, 17, 777-787.
16. Pandey R, Sharma S, Khuller GK. (2006). Chemotherapeutic efcacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv, 13, 287-294. (Pubitemid 43739140)
17. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. (2010). Gelatin nanocarriers as potential vectors for efective management of tuberculosis. Int J Pharm, 385, 143-149.
18. Sharma A, Sharma S, Khuller GK. (2004). Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother, 54, 761-766. (Pubitemid 39386728)
19. Swenson CE, Stewart KA, Hammett JL, Fitzsimmons WE, Ginsberg RS. (1990). Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother, 34, 235-240 (Pubitemid 20046872)
20. du Toit LC, Pillay V, Danckwerts MP. (2006). Tuberculosis chemotherapy: current drug delivery approaches. Respir Res, 7, 118.
21. Uto T, Wang X, Sato K, Haraguchi M, Akagi T, Akashi M, Baba M. (2007). Targeting of Antigen to Dendritic Cells with Poly (γ glutamic acid) nanoparticles induces antigen specifc humoral and cellular immunity. J Imm, 178, 2979-2986. (Pubitemid 46333177)
22. Van den Broek PJ, Buys LF, van den Barselaar MT, Leijh PC, van Furth R. (1986). Infuence of human monocytes on the antibacterial activity of kanamycin and gentamicin for Staphylococcus aureus. Antimicrob Agents Chemother, 29, 1032-1039. (Pubitemid 16084066)
23. Vandervoort J, Ludwig A. (2004). Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm, 57, 251-261. (Pubitemid 38283701)
24. WHO. (2008). Global Tuberculosis Control Surveillance, Planning, Financing. http://www.who.int/tb/publications/global-report/2008/pdf/fullreport. pdf (Accessed 30 April 2009).
25. Zahoor A, Pandey R, Sharma S, Khuller GK. (2006). Evaluation of antitubercular drug loaded alginate nanoparticles against experimental tuberculosis. J Nanoscience, 1, 81-85.